Evaxion biotech announces fourth quarter and full year 2021 financial results and provides business update

Copenhagen, denmark, march 22, 2022 (globe newswire) -- evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage biotechnology company specializing in the development of ai-driven immunotherapies, announced today the fourth quarter and full-year 2021 financial results and provided an operational update.

EVAX Ratings Summary

EVAX Quant Ranking